Mode
Text Size
Log in / Sign up
N/A Completed N=320 Randomized Supportive Care

Clinical Benefits of a Blood Glucose Monitoring System in Patients With Type 2 Diabetes

Source: ClinicalTrials.gov NCT00401622 ↗
Enrolled (actual)
320
Serious AEs
0.3%
Results posted
Sep 2010
Primary outcomePrimary: Change in A1C From Baseline to Week 52 Between the OneTouch® Ultra®2 and Control BGMS. — -0.35; -0.18 Percentage — p=0.45

Summary

Clinical benefits of the OneTouch® Ultra®2 BGMS versus standard BGMS during 52 weeks of use.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in A1C From Baseline to Week 52 Between the OneTouch® Ultra®2 and Control BGMS.
-0.35; -0.18 0.45
SECONDARY
Change in Daily Glycemic Excursions Between the OneTouch® Ultra®2 and Control BGMS.
102.7; 105.8 0.31

Eligibility Criteria

Inclusion Criteria:·

  • Current diagnosis of type 2 diabetes
  • Diagnosed at least 3 months prior to the start of the study but not more than 15 years from the start of the study
  • Stable regimen (i.e., no changes in therapeutic regimen) for the past three months
  • Baseline HbA1c of 7.0 to 8.9%, inclusive

Exclusion Criteria

  • Using insulin
  • Using oral agents that target post-prandial hyperglycemia (Note: These medications may be added during the study)
  • Known history of anemia or disorders associated with anemia
  • Has previously used the devices being tested in the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00401622). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search